ASGCT: The Home of Cell and Gene Therapy

(3:32)

Welcome to ASGCT: Who We Are and What We Do

(2:38)

ASGCT 2022 Presentation Preview

(2:24)

ASGCT 2023 Presentation Overview

(1:35)

Welcome to ASGCT: Become a Member

(2:21)

Gene Insertion Tech with Jason Cole, CEO of SalioGen—ASGCT's The Issue

(48:15)

Regulatory Landscapes in CGT with Sabrina Mogle—ASGCT's The Issue

(47:6)

What's it Like to Attend the ASGCT Annual Meeting?

(4:7)

Gene-editing Technologies: Powerful Tools Rewriting the Code of Life

(52:59)

STXBP1 Science + Love = Cure 10 Minute Updates #14

(25:49)

CAR T-Cell Therapy: How Does It Work?

(2:21)

Viral Vectors Overview

(4:43)

Reducing the Immunogenicity of AAV through Engineering the Vector - George Church

(18:36)

AAV Vector Manufacturing and Analytics

(33:36)

Gene Therapy for GM1 Gangliosidosis

(2:48)

Modifying Cell Identity Through Reprogramming

(7:24)

Short and Long Read Sequencing for AAV Characterization: BIO-ASGCT CGT Science Series

(57:44)

Pompe Disease and Gene Therapy

(4:5)

ASGCT 2024 Abstract Highlights with Chris Leidli, Emily Walsh Martin, and Lynnea Olivarez

(45:1econd)

Around the World: Australasian Gene and Cell Therapy Society (AGCTS)

(56:13)

ASGCT 2021 Presidential Symposium: Robert L. Martuza, M.D.

(45:22)

ASGCT Recap 2023

(4:)

Recent CMC Guidance for Cellular and Gene Therapies: BIO-ASGCT CGT Science Series

(55:21)

Reprogramming Human T Cell Circuitry - Alexander Marson

(31:41)

Policy and Advocacy Shorts with Katy Spink, PhD

(31)

CRISPR and Beyond with Vertex CSO David Altshuler, MD, PhD—ASGCT's The Issue

(48:53)

Demo Duck \u0026 ASGCT: Video Production Partnership

(1:28)

Welcome to the Annual Meeting with ASGCT President Jeff Chamberlain, PhD

(5:4)